Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | CASP8 | Q14790 | 4/20 | 0.31 |
| ▸ | CASP1 | P29466 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25262408 | 0.72 | BRD4 (0.34) | SMN1; SMN2CASP3CASP8CASP1 | |
| SCHEMBL25220381 | 0.72 | BRD4 (0.34) | SMN1; SMN2CASP3CASP8CASP1 | |
| SCHEMBL25274007 | 0.72 | BRD4 (0.34) | SMN1; SMN2CASP3CASP8CASP1 | |
| SCHEMBL25268709 | 0.72 | BRD4 (0.34) | SMN1; SMN2CASP3CASP8CASP1 | |
| SCHEMBL26623259 | 0.70 | CASP3 (0.35) | SMN1; SMN2CASP3CASP8CASP1 | |
| SCHEMBL26623252 | 0.70 | CASP3 (0.35) | SMN1; SMN2CASP3CASP8CASP1 | |
| SCHEMBL6200874 | 0.70 | CASP3 (0.35) | SMN1; SMN2CASP3CASP8CASP1 | |
| SCHEMBL19941102 | 0.67 | SMN1; SMN2 (0.48) | SMN1; SMN2 | |
| SCHEMBL10102999 | 0.67 | SMN1; SMN2 (0.42) | SMN1; SMN2 | |
| SCHEMBL1106133 | 0.67 | SMN1; SMN2 (0.38) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | SMN1; SMN2 666/4885CASP3 642/4885GAA 4849/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | SMN1; SMN2 473/4885CASP3 861/4885GAA 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.